In the SARS-CoV-2 pandemic: Outpatient management of the diabetes patient
PDF (Español (España))
HTML (Español (España))


Diabetes Mellitus

How to Cite

Ramírez-Rincón, A., & Builes-Montaño, C. E. (2020). In the SARS-CoV-2 pandemic: Outpatient management of the diabetes patient. Revista Colombiana De Endocrinología, Diabetes &Amp; Metabolismo, 7(2S), 72–75.


Outpatient treatment of patients with Chronic Noncommunicable Diseases (CNCD) offers interesting challenges in the context of the SARS-CoV-2 (COVID-19) pandemic, thus Diabetes requires an individual analysis. It is a place to discuss elements of outpatient treatment: from implementation of specific models, recommendations for changes in lifestyle, orientation in comorbidities, identification of additional risk factors, to suggestions in each of the pharmacological groups that are involved here. All of the above in order to provide the best support to patients in the non-hospital setting.
PDF (Español (España))
HTML (Español (España))


1.Bornstein SR, Rubino F, Khunti K, Mingrone G, Hopkins D, Birkenfeld A, et al. Practical recommendations for the management of diabetes inpatients with COVID-19. Lancet Diabetes Endocrinol. 2020;8(6):546-50. doi: 10.1016/S2213-8587(20)30152-2.
2. Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr. 2020;14(4):303-10. doi: 10.1016/j.dsx.2020.04.004.
3. Drucker DJ. Coronavirus Infections and Type 2 Diabetes-Shared Pathways With Therapeutic Implications. Endocr Rev. 2020;41(3):bnaa011. doi:10.1210/endrev/bnaa011.
4. Gupta R, Ghosh A, Singh ak, Misra a. Clinical considerations for patients with diabetes in times of COVID-19 epidemic. Diabetes Metab Syndr. 2020;14(3):211-2. doi:10.1016/j.dsx.2020.03.002.
5. de Simone G. Position statement of the ESC Council on Hypertension on ACE-inhibitors and angiotensin receptor blockers [Internet]. [Consultado 15 de abril de 2020]. Disponible en:
6. Raj VS, Mou H, Smits SL, Dekkers DHW, Müller MA, Dijkman R, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature. 2013;495(7440):251-4. doi: 10.1038/nature12005.
7. Andersen CJ, Murphy KE, Fernandez ML. Impact of obesity and metabolic syndrome on immunity. Adv Nutr. 2016;7(1):66-75. doi: 10.3945/ an.115.010207.
8. International Diabetes Federation Europe. How to manage diabetes during an illness? “Sick Day Rules” [Internet]. Disponible en: https://bit. ly/3cg3urt.
9. Cameron AR, Morrison VL, Levin D, Mohan M, Forteath C, Beall C, et al. Anti-Inflammatory effects of metformin irrespective of diabetes status. Circ Res. 2016;119(5):652-65. doi: 10.1161/CIRCRESAHA.116.308445.
10. Iacobellis G. COVID-19 and diabetes: Can DPP4 inhibition play a role? Diabetes Research Clin Pract. 2020;162:108125. doi: 10.1016/j.diabres.2020.108125.
11. Mulvihill EE, Drucker DJ. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr Rev. 2014;35(6):992- 1019. doi:10.1210/er.2014-1035.
12. Zhou F, Zhang Y, Chen J, Hu X, Xu Y. Liraglutide attenuates lipopolysaccharide induced acute lung injury in mice. Eur J Pharmacol. 2016;791:735-40. doi:10.1016/j.ejphar.2016.10.016.
13. Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740-56. doi: 10.1016/j. cmet.2018.03.001.
14. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann J, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311-22. doi: 10.1056/NEJMoa1603827.
15. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834-44. doi: 10.1056/NEJMoa1607141.
16. Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al. Effects of once weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228-39. doi: 10.1056/NEJMoa1612917.
17. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121-30. doi: 10.1016/S0140-6736(19)31149-3.
18. American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S98-S110. doi: 10.2337/dc20-S009.
19. Hamblin PS, Wong R, Ekinci EI, Fourlanos S, Shah S, Jones A, et al. SGLT2 inhibitors increase the risk of diabetic ketoacidosis developing in the community and during hospital admission. J Clin Endocrinol Metab. 2019;104(8):3077-87. doi: 10.1210/jc.2019-00139.
20. Royal United Hospitals Bath. NHS Foundation Trust. Urgent Safety Notice: Use of SGLT-2 inhibitor during the COVID-19 crisis [Internet]. Disponible en:
21. Kosiborod M. Dapagliflozin in Respiratory Failure in Patients With COVID-19 (DARE-19) [Internet]. Disponible en:
22. Tsai S, Clemente-Casares X, Zhou AC, Lei H, Ahn JJ, Chan YT, et al. Insulin receptor-mediated stimulation boosts T cell immunity during inflammation and infection. Cell Metab. 2018;28(6):922-934.e924. doi: 10.1016/j.cmet.2018.08.003.
23. Hansen TK, Thiel S, Wouters PJ, Christiansen JS, Van den Berghe G. Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. J Clin Endocrinol Metab. 2003;88(3):1082-8. doi: 10.1210/jc.2002-021478.

Authors must state that they reviewed, validated and approved the manuscript's publication.  Moreover, they must sign a model release that should be sent.  A copy may be reviewed here




Download data is not yet available.